Aimei Health Technology Co., Ltd. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Aimei Health Technology Co., Ltd. has filed its 2023 annual report on Form 10-K.</b>

AI Summary

Aimei Health Technology Co., Ltd. (AFJKR) filed a Annual Report (10-K) with the SEC on March 25, 2024. Aimei Health Technology Co., Ltd. filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The filing was submitted on March 25, 2024. The company's principal executive offices are located at 10 East 53rd Street, Suite 3001, New York, NY 10022. The report covers the fiscal year ending December 31, 2023. The filing is a transition report under Section 13 or 15(d) of the Securities Exchange Act of 1934.

Why It Matters

For investors and stakeholders tracking Aimei Health Technology Co., Ltd., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Aimei Health Technology's financial performance and business operations for the fiscal year 2023. Investors and stakeholders can use this report to assess the company's financial health, strategic direction, and potential risks.

Risk Assessment

Risk Level: — Aimei Health Technology Co., Ltd. shows moderate risk based on this filing. The filing is a standard annual report (10-K) and does not contain immediate, significant financial disclosures or events that would indicate high risk.

Analyst Insight

Review the full 10-K filing for detailed financial statements, risk factors, and management's discussion and analysis to understand Aimei Health Technology's performance and outlook.

Key Players & Entities

• Aimei Health Technology Co., Ltd. (company) — Filer of the 10-K report
• 2023-12-31 (date) — Fiscal year end
• 2024-03-25 (date) — Filing date
• 10 East 53rd Street, Suite 3001, New York, NY 10022 (address) — Company business address
• Securities Exchange Act of 1934 (regulation) — Act under which the report is filed

FAQ

Industry Context

The filing pertains to a company operating within the health technology sector, though specific industry details are not provided in this header information.

Regulatory Implications

The report is filed under the Securities Exchange Act of 1934, a key piece of U.S. federal legislation regulating the secondary trading of securities.

What Investors Should Do

1. Analyze the financial statements (balance sheet, income statement, cash flow) within the 10-K.
2. Review the 'Management's Discussion and Analysis of Financial Condition and Results of Operations' section for insights into performance drivers.
3. Examine the 'Risk Factors' section for potential challenges and uncertainties facing the company.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K
• 2024-03-25: Filing Date — Date the 10-K was officially submitted to the SEC

Year-Over-Year Comparison

This is the initial 10-K filing for the fiscal year ended December 31, 2023, as indicated by the filing date and period covered.

Key Financial Figures

• $10.00 — g of 6,900,000 units (the " Units ") at $10.00 per Unit. Each Unit consists of one ord
• $0.0001 — ch Unit consists of one ordinary share, $0.0001 par value (" Ordinary Share "), and one
• $69,000,000 — per Unit, generating gross proceeds of $69,000,000. The Company had granted the underwrite
• $2,070,665 — The Company incurred offering costs of $2,070,665 and $690,000 for deferred underwriting
• $690,000 — curred offering costs of $2,070,665 and $690,000 for deferred underwriting commissions.
• $3,320,000 — Units "), generating total proceeds of $3,320,000. The Private Units are identical to the
• $69,690,000 — ring. On December 6, 2023, a total of $69,690,000 of the net proceeds from the sale of Un
• $50,000 — t (net of taxes payable, and less up to $50,000 of interest to pay liquidation expenses

Filing Documents

• form10-k.htm (10-K) — 774KB
• ex4-5.htm (EX-4.5) — 40KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32.htm (EX-32) — 10KB
• ex97-1.htm (EX-97.1) — 32KB
• 0001493152-24-011146.txt (&nbsp;) — 3189KB
• afjk-20231231.xsd (EX-101.SCH) — 23KB
• afjk-20231231_cal.xml (EX-101.CAL) — 25KB
• afjk-20231231_def.xml (EX-101.DEF) — 119KB
• afjk-20231231_lab.xml (EX-101.LAB) — 183KB
• afjk-20231231_pre.xml (EX-101.PRE) — 163KB
• form10-k_htm.xml (XML) — 248KB

BUSINESS

BUSINESS 1 ITEM 1A. RISK FACTORS 22 ITEM 1B. UNRESOLVED STAFF COMMENTS 22 ITEM 2.

PROPERTIES

PROPERTIES 22 ITEM 3. LEGAL PROCEEDINGS 22 ITEM 4. MINE SAFETY DISCLOSURES 22 PART II 23 ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED SHAREHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES 23 ITEM 6. [RESERVED] 23 ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 23 ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 25 ITEM 8. CONSOLIDATED

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA 25 ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE 25 ITEM 9A. CONTROLS AND PROCEDURES 26 ITEM 9B. OTHER INFORMATION 26 ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 26 PART III 27 ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE 27 ITEM 11. EXECUTIVE COMPENSATION 33 ITEM 12. SECURITY 34 ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 35 ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES 37 PART IV 38 ITEM 15. EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES 38 i CERTAIN TERMS References to " Aimei ," the " Company ," " our ," " us " or " we " refer to Aimei Health Technology Co., Ltd., a blank check company incorporated as a Cayman Islands exempted company on April 27, 2023 . References to our " Sponsor " refer to Aimei Investment Ltd, a Cayman Islands exempted company. References to our " IPO " refer to the initial public offering of Aimei, which closed on December 6, 2023. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. The statements contained in this report that are not purely historical are forward-looking statements. Our forward-looking statements include, but are not limited to, statements regarding our or our management's expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any assumptions, are forward-looking statements. The words "anticipates,

View Full Filing

View this 10-K filing on SEC EDGAR